<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="685">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 07, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02085265</url>
  </required_header>
  <id_info>
    <org_study_id>SARTAN-AD-001</org_study_id>
    <nct_id>NCT02085265</nct_id>
  </id_info>
  <brief_title>Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients</brief_title>
  <acronym>SARTAN-AD</acronym>
  <official_title>The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Sandra E Black</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer’s Drug Discovery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to conduct a proof of concept study in patients with probable
      Alzheimer's Disease who have mild to moderate hypertension, in order to determine if there is
      less global brain atrophy over one year, as measured by ventricular enlargement as a primary
      outcome measure, when patients are randomized to treatment with an angiotensin receptor
      blocker compared to an Angiotensin Converting Enzyme inhibitor (ACEI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study uses a simple validated measure of brain atrophy as a surrogate marker in a
      repurposing effort that could recast an antihypertensive medication as a cognitive enhancer
      /neuroprotective agent and possibly as a drug of choice for Alzheimer patients and patients
      at risk for AD. If the proof of concept result is positive, a larger study would be warranted
      with potential practice-changing impact.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventricular enlargement</measure>
    <time_frame>12 months</time_frame>
    <description>Change in ventricular size, on 3D T1 MR imaging, after 12 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Change in blood pressure (BP) measurements after 12 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Vital signs</measure>
    <time_frame>12 months</time_frame>
    <description>Change in vital sign (heart rate, pulse) measurements after 12 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Electrolytes</measure>
    <time_frame>12 months</time_frame>
    <description>Change in electrolyte measurements (Na, K) after 12 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events and serious adverse events over 12 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hippocampal volume</measure>
    <time_frame>12 months</time_frame>
    <description>Change in hippocampal volume measurements after 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grey/White matter volume</measure>
    <time_frame>12 months</time_frame>
    <description>Volume of grey and white matter in the cingulate, parietotemporal and dorsolateral frontal regions after 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive and functional measures</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Neuropsychiatric Measures</measure>
    <time_frame>6 &amp; 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 &amp; 12 months</time_frame>
    <description>Change in caregiver burden and health-related quality of life after treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment responsiveness of Diffusion Tensor Imaging (DTI)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Treatment responsiveness of resting state functional MRI (rsfMRI)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perindopril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril</intervention_name>
    <description>Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)</description>
    <arm_group_label>Perindopril</arm_group_label>
    <other_name>Coversyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)</description>
    <arm_group_label>Telmisartan</arm_group_label>
    <other_name>teva-telmisartan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Previously established clinical diagnosis of probable AD dementia by the new McKhann
             criteria63

          2. Previous brain MRI or CT scan within the last 2 years to rule out exclusionary
             pathology, such as cortical stroke, tumour, subdural hematomas, malformations, etc.

          3. Age 55 years or older

          4. Established diagnosis of hypertension and on at least one hypertensive medication

          5. Standardized Mini Mental State Examination (SMMSE) score of 16-27 at screening visit

          6. Sufficient hearing and vision to participate in testing as per investigator's
             judgement

          7. Sufficient fluency in English to be able to complete language and other cognitive
             tests

          8. At least 8 years of education

          9. A study partner who in the opinion of the study investigator has regular interaction
             with the patient, can be present for all clinic visits, can provide a collateral
             history and can assist in compliance with study procedures

         10. Stable dose of a cholinesterase inhibitor (ChEI) and/or memantine for at least 3
             months prior to the randomization visit

         11. HbA1C &lt;8.5%. Patients with stable type II diabetes are eligible for the study if the
             following conditions are met: there have been no severe hypoglycemic events requiring
             third party intervention (e.g. emergency department visit) within 6 months, and
             medication therapy has been stable for at least 3 months and is limited to oral
             antidiabetic agents and/or basal insulin therapy no more than once per day

         12. Patients on medications for vascular risk factors (e.g., hypertension, cholesterol)
             must be on a stable dose for ≥3 months prior to randomization.

        Exclusion criteria

          1. Intolerance, or any contraindications, to study medications

          2. Familial autosomal dominant form of Alzheimer's disease

          3. Creatinine clearance less than or equal to 30ml/min

          4. Serum potassium &gt; 5.5 mEq/L

          5. ALT &gt; the upper limit of normal (ULN)

          6. History of angioedema

          7. Co-morbid acute or chronic conditions (including type I diabetes mellitus, stroke,
             other neurological conditions such as Parkinson's disease, and psychiatric disorders,
             and severe or unstable medical conditions) that could confound assessments or would,
             in the judgment of the investigator, make the subject inappropriate for entry into
             this study

          8. Severe periventricular white matter disease (Fazekas score 3), cortical infarction,
             lacunar infarcts &lt;1.5 cm diameter in basal ganglia or thalamus or &gt;2 lacunar infarcts
             (&lt;1.5cm diameter) elsewhere on screening MRI

          9. Inability to perform the study procedures, including claustrophobia or
             contraindications for MRI

         10. Currently on or has taken an angiotensin receptor blocker within 12 months of
             randomization visit

         11. Resides in a nursing home (participants who reside in retirement homes may be included
             if they have a study partner who meets inclusion criterion #9)

         12. Current major depression by clinical history or score greater than 18 on the Cornell
             Scale for Depression in Dementia

         13. Documented potential cardiac source of brain infarction such as mechanical valve or
             any type of atrial fibrillation

         14. Regular use of psychotropic medications, other than a short-acting benzodiazepine for
             sleep or non-anticholinergic antidepressants (stable dose for 3 months at time of
             randomization); exceptions (e.g. for antipsychotic medication) may be permitted on a
             case-by-case basis, upon consultation with Dr. Krista Lanctôt
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Black, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krista Lanctot, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Black, MD</last_name>
    <phone>416.480.4551</phone>
    <email>sandra.black@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parkwood Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 4R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Borrie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ljubica Zotovic, MD</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>3004</phone_ext>
      <email>ljubica.zotovic@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Sandra Black, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Corinne Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- Old date names will be dropped in a few months (sometime in 2018)                        -->
  <lastchanged_date>December 21, 2015</lastchanged_date>
  <firstreceived_date>November 29, 2013</firstreceived_date>
  <!-- New date names                                                                           -->
  <study_first_submitted>November 29, 2013</study_first_submitted>
  <study_first_submitted_qc>March 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2014</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <!-- End of dates                                                                             -->
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Sandra E Black</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Perindopril</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>Brain atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

